Elequin Capital’s Roivant Sciences ROIV Stock Holding History

Elequin Capital’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1	Closed	-$7	–	603
2023 Q1	$7	Buy	+1	New	+$8	﹤0.01%	301

Other funds holding ROIV

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Elequin Capital's ROIV Position: Q2 2023 in Review

Elequin Capital sold out of Roivant Sciences (ROIV) in Q2 2023, closing a stake of 1 share — an estimated $7 sold.

Elequin Capital first reported a position in ROIV in Q1 2023 and held it in 1 quarter. The position peaked at $7 in Q1 2023. 181 funds tracked by Wall St. Rank hold ROIV as of Q2 2023.

Elequin Capital reported no remaining Roivant Sciences position as of Q2 2023 after selling out during the quarter.
Elequin Capital sold 1 Roivant Sciences share in Q2 2023, an estimated $7.
Elequin Capital first reported a position in Roivant Sciences in Q1 2023 and held it in 1 quarter.
Elequin Capital's Roivant Sciences position peaked at $7 in Q1 2023.
181 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2023.

Based on Elequin Capital's 13F filing for Q2 2023, filed 14 Aug 2023.